{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:34:09Z","timestamp":1790202849316,"version":"4.1.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Coenzyme Q10 (CoQ10), or ubiquinone, is a lipid-soluble antioxidant essential for mitochondrial adenosine triphosphate production and cellular energy metabolism. Its therapeutic potential has been investigated in conditions marked by mitochondrial dysfunction, particularly chronic heart failure and statin-associated muscle symptoms. Robust evidence, including data from the Q-SYMBIO trial, demonstrates that CoQ10 supplementation can improve functional capacity, ejection fraction, and reduce major cardiovascular events in heart failure with reduced ejection fraction. However, studies on its efficacy for statin myopathy have yielded inconsistent results, with some reporting symptom relief and others showing no significant benefit. CoQ10 is generally safe, well-tolerated, and affordable, and emerging research supports its classification as a conditionally essential nutrient in heart failure. While routine supplementation for all statin users is not currently recommended, targeted use in advanced heart failure with reduced ejection fraction or in patients with high mitochondrial demand may be justified. As further evidence and cost-effectiveness data become available, formal guideline recommendations for CoQ10 may follow.<\/jats:p>","DOI":"10.1097\/crd.0000000000001135","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:00:11Z","timestamp":1768194011000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Coenzyme Q10 in Cardiovascular Medicine: Mechanisms, Clinical Evidence, and Future Integration in Heart Failure and Statin Myopathy"],"prefix":"10.1097","author":[{"given":"Jacqueline","family":"Kumble","sequence":"first","affiliation":[{"name":"New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"New York Medical College, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"R1-20260112","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/07315724.2001.10719063","article-title":"Biochemical functions of coenzyme Q10.","volume":"20","author":"Crane","year":"2001","journal-title":"J Am Coll Nutr"},{"key":"R2-20260112","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/biof.154","article-title":"Coenzyme Q10, endothelial function, and cardiovascular disease.","volume":"37","author":"Littarru","year":"2011","journal-title":"Biofactors"},{"key":"R3-20260112","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0006-3002(57)90457-2","article-title":"Isolation of a quinone from beef heart mitochondria.","volume":"25","author":"Crane","year":"1957","journal-title":"Biochim Biophys Acta"},{"key":"R4-20260112","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.mito.2007.02.011","article-title":"Discovery of ubiquinone (coenzyme Q) and an overview of function.","volume":"7","author":"Crane","year":"2007","journal-title":"Mitochondrion"},{"key":"R5-20260112","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/biof.5520180210","article-title":"Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of \u201cQ-symbio\u201d\u2013a multinational trial.","volume":"18","author":"Mortensen","year":"2003","journal-title":"BioFactors"},{"key":"R6-20260112","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jacc.2008.07.044","article-title":"Coenzyme Q10: an independent predictor of mortality in chronic heart failure.","volume":"52","author":"Molyneux","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R7-20260112","doi-asserted-by":"crossref","first-page":"797-","DOI":"10.1592\/phco.21.9.797.34564","article-title":"Role of coenzyme Q10 in chronic heart failure, angina, and hypertension.","volume":"21","author":"Tran","year":"2001","journal-title":"Pharmacotherapy"},{"key":"R9-20260112","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/acm.2019.0128","article-title":"Internet marketing of cardioprotective dietary supplements.","volume":"26","author":"Bjelica","year":"2020","journal-title":"J Altern Complement Med"},{"key":"R10-20260112","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/0098-2997(94)90037-X","article-title":"Treatment of essential hypertension with coenzyme Q10.","volume":"15","author":"Langsjoen","year":"1994","journal-title":"Mol Aspects Med"},{"key":"R11-20260112","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jchf.2014.06.008","article-title":"The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure.","volume":"2","author":"Mortensen","year":"2014","journal-title":"JACC Heart Fail"},{"key":"R12-20260112","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review.","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R13-20260112","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/1541-4337.12539","article-title":"Coenzyme Q10 supplementation: efficacy, safety, and formulation challenges.","volume":"19","author":"Arenas\u2010Jal","year":"2020","journal-title":"Comp Rev Food Sci Food Safe"},{"key":"R14-20260112","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2005.12.002","article-title":"Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial.","volume":"44","author":"Ikematsu","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"key":"R15-20260112","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0925-4439(95)00028-3","article-title":"Biochemical, physiological and medical aspects of ubiquinone function.","volume":"1271","author":"Ernster","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"R16-20260112","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1152\/physrev.00006.2014","article-title":"Electronic connection between the quinone and cytochrome C redox pools and its role in regulation of mitochondrial electron transfer chain signalling.","volume":"95","author":"Sarewicz","year":"2015","journal-title":"Physiol Rev"},{"key":"R17-20260112","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ddrr.108","article-title":"Coenzyme Q and mitochondrial disease.","volume":"16","author":"Quinzii","year":"2010","journal-title":"Dev Disabil Res Rev"},{"key":"R18-20260112","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s11064-006-9190-z","article-title":"Human coenzyme Q10 deficiency.","volume":"32","author":"Quinzii","year":"2007","journal-title":"Neurochem Res"},{"key":"R20-20260112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/biof.5520250115","article-title":"Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure.","volume":"25","author":"Belardinelli","year":"2005","journal-title":"Biofactors"},{"key":"R21-20260112","doi-asserted-by":"crossref","first-page":"s273","DOI":"10.1016\/0098-2997(94)90038-8","article-title":"Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers.","volume":"15","author":"Weis","year":"1994","journal-title":"Mol Aspects Med"},{"key":"R22-20260112","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.nut.2018.05.020","article-title":"Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization.","volume":"57","author":"L\u00f3pez-Lluch","year":"2019","journal-title":"Nutrition"},{"key":"R23-20260112","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2006.10.007","article-title":"Assessment of coenzyme Q10 absorption using an in vitro digestion-Caco-2 cell model.","volume":"333","author":"Bhagavan","year":"2007","journal-title":"Int J Pharm"},{"key":"R24-20260112","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0271-5317(02)00402-5","article-title":"Bioequivalence of coenzyme Q10 from over-the-counter supplements.","volume":"22","author":"Miles","year":"2002","journal-title":"Nutr Res"},{"key":"R25-20260112","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/ajhp\/57.13.1221","article-title":"Potential interactions between alternative therapies and warfarin.","volume":"57","author":"Heck","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"R26-20260112","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0735-1097(98)00101-6","article-title":"Increased oxidative stress in patients with congestive heart failure.","volume":"31","author":"Keith","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"R27-20260112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.2003.055095","article-title":"Energy metabolism in heart failure.","volume":"555","author":"Ventura-Clapier","year":"2004","journal-title":"J Physiol"},{"key":"R28-20260112","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10715760600617843","article-title":"Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics.","volume":"40","author":"Bhagavan","year":"2006","journal-title":"Free Radic Res"},{"key":"R29-20260112","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/biof.5520180210","article-title":"Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of \u201cQ-symbio\u201d\u2013a multinational trial.","volume":"18","author":"Mortensen","year":"2003","journal-title":"Biofactors"},{"key":"R30-20260112","first-page":"null","article-title":"Coenzyme Q10 for heart failure.","volume":"2021","author":"Al Saadi","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"R31-20260112","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12872-017-0628-9","article-title":"Meta-analysis of coenzyme Q10 in patients with heart failure.","volume":"17","author":"Lei","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"R32-20260112","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of \u226550.","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ Heart Fail"},{"key":"R33-20260112","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/sj.jhh.1002138","article-title":"Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials.","volume":"21","author":"Rosenfeldt","year":"2007","journal-title":"J Hum Hypertens"},{"key":"R34-20260112","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00125-001-0760-y","article-title":"Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus.","volume":"45","author":"Watts","year":"2002","journal-title":"Diabetologia"},{"key":"R35-20260112","first-page":"1299","article-title":"Coenzyme Q10 and cardiovascular bioenergetics: from bench to bedside.","volume":"49","author":"Littarru","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"R36-20260112","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1073\/pnas.87.22.8931","article-title":"Lovastatin decreases coenzyme Q levels in humans.","volume":"87","author":"Folkers","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R37-20260112","first-page":"16","article-title":"Coenzyme q10 and statin-induced mitochondrial dysfunction.","volume":"10","author":"Deichmann","year":"2010","journal-title":"Ochsner J"},{"key":"R38-20260112","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/jcm6080075","article-title":"Statins, Muscle Disease and Mitochondria.","volume":"6","author":"Ramachandran","year":"2017","journal-title":"J Clin Med"},{"key":"R39-20260112","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/biof.5520180212","article-title":"The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications.","volume":"18","author":"Langsjoen","year":"2003","journal-title":"BioFactors"},{"key":"R40-20260112","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0009-9236(95)90266-X","article-title":"\u201cDecreases in serum ubiquinone concentrations do not parallel changes in serum cholesterol during short-term simvastatin treatment in humans.\u201d.","volume":"57","author":"Laaksonen","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R41-20260112","first-page":"1011","article-title":"Statin-associated myopathy with normal creatine kinase levels.","volume":"58","author":"Phillips","year":"2002","journal-title":"Neurology"},{"key":"R42-20260112","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials.","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"R43-20260112","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study.","volume":"20","author":"Skarlovnik","year":"2014","journal-title":"Med Sci Monit"},{"key":"R44-20260112","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials.","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"R45-20260112","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study.","volume":"20","author":"Skarlovnik","year":"2014","journal-title":"Med Sci Monit"},{"key":"R46-20260112","doi-asserted-by":"crossref","first-page":"e009835","DOI":"10.1161\/JAHA.118.009835","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials.","volume":"7","author":"Qu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R47-20260112","first-page":"828803","article-title":"Effect of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials with trial sequential analysis.","volume":"13","author":"Qu","year":"2022","journal-title":"Front Pharmacol"},{"key":"R48-20260112","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11936-009-0027-3","article-title":"Management of the statin-intolerant patient.","volume":"11","author":"Smiley","year":"2009","journal-title":"Curr Treat Options Cardio Med"},{"key":"R49-20260112","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.","volume":"59","author":"Shults","year":"2002","journal-title":"Arch Neurol"},{"key":"R50-20260112","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol"},{"key":"R51-20260112","first-page":"1793","article-title":"Effects of coenzyme Q10 supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials.","volume":"42","author":"Zheng","year":"2019","journal-title":"Diabetes Care"},{"key":"R52-20260112","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mus.22047","article-title":"CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy.","volume":"44","author":"Spurney","year":"2011","journal-title":"Muscle Nerve"},{"key":"R53-20260112","first-page":"1336","article-title":"Coenzyme Q10 deficiencies and disorders of the ubiquinone biosynthetic pathway.","volume":"79","author":"Hirano","year":"2012","journal-title":"Neurology"},{"key":"R54-20260112","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.juro.2009.02.121","article-title":"Efficacy of Coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men.","volume":"182","author":"Safarinejad","year":"2009","journal-title":"J Urol"},{"key":"R55-20260112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/CMRH.S14681","article-title":"Coenzyme Q10 supplementation and oocyte aneuploidy in women undergoing IVF-ICSI treatment.","volume":"8","author":"Bentov","year":"2014","journal-title":"Clin Med Insights Reprod Health"},{"key":"R56-20260112","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10741-006-9195-3","article-title":"The management of conditioned nutritional requirements in heart failure.","volume":"11","author":"Allard","year":"2006","journal-title":"Heart Fail Rev"},{"key":"R57-20260112","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00059-002-2360-0","article-title":"Conditioned nutritional requirements: therapeutic relevance to heart failure.","volume":"27","author":"Sole","year":"2002","journal-title":"Herz"},{"key":"R58-20260112","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/joim.13456","article-title":"Micronutrient deficiencies in heart failure: mitochondrial dysfunction as a common pathophysiological mechanism?","volume":"291","author":"Bomer","year":"2022","journal-title":"J Intern Med"},{"key":"R59-20260112","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure.","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R62-20260112","first-page":"e009099","article-title":"Out-of-Pocket Costs for SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction.","volume":"14","author":"Greene","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R63-20260112","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R64-20260112","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1253\/circj.CJ-21-0431","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and Chronic Heart Failure.","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"R65-20260112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0098-2997(97)00014-9","article-title":"Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.","volume":"18","author":"Mortensen","year":"1997","journal-title":"Mol Aspects Med"},{"key":"R66-20260112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12033-007-0052-y","article-title":"Bioenergetic and antioxidant properties of coenzyme Q10: recent developments.","volume":"37","author":"Littarru","year":"2007","journal-title":"Mol Biotechnol"},{"key":"R67-20260112","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/nu12030784","article-title":"Comparative bioavailability of different coenzyme q10 formulations in healthy elderly individuals.","volume":"12","author":"Pravst","year":"2020","journal-title":"Nutrients"},{"key":"R68-20260112","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/biof.5520090224","article-title":"Overview of the use of CoQ10 in cardiovascular disease.","volume":"9","author":"Langsjoen","year":"1999","journal-title":"BioFactors"},{"key":"R69-20260112","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/antiox9050386","article-title":"Bioavailability of coenzyme Q10: an overview of the absorption process and subsequent metabolism.","volume":"9","author":"Mantle","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"R70-20260112","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0955-2863(99)00074-1","article-title":"Piperine derived from black pepper increases the plasma levels of coenzyme q10 following oral supplementation.","volume":"11","author":"Badmaev","year":"2002","journal-title":"The Journal of Nutritional Biochemistry"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:00:19Z","timestamp":1768194019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":66,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001135","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}